Cardio3 BioSciences Announces Results of the C-Cure Phase II Clinical Trial
Positive Results for Innovative Heart-Specified Stem Cell Therapy Underscores Generalized Therapeutic Benefit in Heart Failure
07-Apr-2011 -
Cardio3 BioSciences presented detailed data from the Phase II clinical trial of C3BS-CQR-1 (C-Cure®), its novel stem cell therapy for ischemic cardiomyopathy, at the 60th annual American College of Cardiology in New Orleans, USA.The data were presented by Dr. Jozef Bartunek, Associate Director of ...
heart failures
StemCells